Randi Hagerman

Randi Hagerman is a Distinguished Professor of Pediatrics at the University of California, Davis, holding the endowed chair in Fragile X Research. She serves as Medical Director of the MIND Institute and Director of the Clinical Trials Program at the MIND Institute. Her work focuses on neurogenetic disorders, particularly Fragile X Syndrome (FXS) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Her research spans molecular mechanisms, clinical trials, and neuroimaging studies in these conditions.

Education details are not explicitly provided in the text, but her roles suggest advanced training in pediatrics and genetics. Her research interests include understanding FXS pathophysiology, developing treatments for FXTAS, and exploring neurobiological markers in premutation carriers.

Her articles emphasize clinical trials (e.g., minocycline, memantine), neuroimaging findings in premutation carriers, and molecular mechanisms underlying FXS. She has contributed to studies on FXTAS motor fiber tract analysis, ERP abnormalities, and drug development for neurodegenerative aspects of these disorders.

• Awarded the Hibbard E Williams Lifetime Achievement Award (2022) for her contributions to medical research.

Her clinical and academic leadership includes directing the MIND Institute’s trials program and overseeing interdisciplinary research teams. She has advised numerous studies on FXS, FXTAS, and related neurodevelopmental disorders, with a focus on translational research.

Labs and collaborations include work at the UC Davis MIND Institute, focusing on fragile X-associated disorders, neuroimaging, and clinical trials. Her research bridges basic science and clinical practice to improve patient outcomes in genetic neurodegenerative conditions.